Compass Therapeutics (NASDAQ:CMPX) Rating Increased to Outperform at Leerink Partners

Compass Therapeutics (NASDAQ:CMPX) was upgraded by equities researchers at Leerink Partners from a “market perform” rating to an “outperform” rating in a research report issued on Wednesday, MarketBeat reports. The firm currently has a $6.00 price target on the stock, up from their prior price target of $4.00. Leerink Partners’ price objective indicates a potential upside of 273.83% from the stock’s current price.

CMPX has been the topic of a number of other research reports. Jefferies Financial Group increased their price objective on Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, February 10th. D. Boral Capital restated a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a research note on Tuesday. Guggenheim began coverage on shares of Compass Therapeutics in a research note on Monday, February 24th. They issued a “buy” rating and a $12.00 price objective for the company. Piper Sandler initiated coverage on shares of Compass Therapeutics in a research report on Wednesday, February 19th. They set an “overweight” rating and a $12.00 target price on the stock. Finally, Wedbush reaffirmed an “outperform” rating and issued a $8.00 price target on shares of Compass Therapeutics in a research report on Tuesday. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Compass Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $11.63.

Compass Therapeutics Stock Performance

Compass Therapeutics stock opened at $1.61 on Wednesday. The company has a 50 day moving average price of $2.78 and a 200 day moving average price of $2.10. The firm has a market capitalization of $221.94 million, a price-to-earnings ratio of -4.34 and a beta of 1.19. Compass Therapeutics has a 52 week low of $0.77 and a 52 week high of $4.08.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). Equities analysts forecast that Compass Therapeutics will post -0.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compass Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in CMPX. Intech Investment Management LLC acquired a new position in shares of Compass Therapeutics during the 3rd quarter worth about $30,000. The Manufacturers Life Insurance Company bought a new stake in shares of Compass Therapeutics in the third quarter valued at approximately $79,000. XTX Topco Ltd acquired a new stake in shares of Compass Therapeutics in the third quarter worth $37,000. Barclays PLC increased its position in Compass Therapeutics by 195.4% during the third quarter. Barclays PLC now owns 170,245 shares of the company’s stock worth $314,000 after acquiring an additional 112,614 shares during the period. Finally, Geode Capital Management LLC raised its stake in Compass Therapeutics by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock valued at $4,251,000 after purchasing an additional 19,095 shares during the last quarter. 68.43% of the stock is owned by institutional investors and hedge funds.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.